Cell line development: how cell line development companies stage the work, what cell line development services, cell line construction and stable cell line generation deliver, and what clonality evidence is required
Cell line development produces the thing every later stage depends on, which is why the evidence generated along the way matters as much as the productivity number at the end. A line that expresses well but cannot be shown to be clonally derived, or that loses expression over the generations a campaign needs, is a line you will develop twice. This page covers the stages, the evidence that has to accompany each, and the questions that separate providers.
- the FDA cGMP rule that applies once material is destined for a drug product
- Part 211
- the ICH guideline on deriving and characterising cell substrates
- Q5D
- good laboratory practice for nonclinical studies, 21 CFR
- Part 58
Figures in this panel are the rules a contract biologics service is bought and audited against, named from the regulations and guidelines themselves and linked in the sources below. They are identifiers, not prices: BioBricks publishes verified prices for synthesis services only, and does not imply a services index it has not measured.
- 4 vendor service pages verifiedevery figure matched verbatim to the vendor's page
- Quoted and dated, never estimatedlast verification pass 2026-08-24
- 1 service classes coveredeach with measured search demand behind it
The stages and their evidence
- Host and vector selection. The host line and the expression vector constrain productivity, product quality and what regulatory history you inherit. Providers offer their own hosts under licence, and the licence terms travel with your programme, so read them before the science starts.
- Pool generation and early assessment. Transfected pools give an early read on whether the molecule expresses and what its quality attributes look like, long before clones exist. Material from a pool is often enough for early studies, and generating it early removes months from a programme's critical path.
- Single cell cloning and clonality evidence. The line must be derived from a single cell, and that has to be evidenced rather than asserted, normally by imaging at the point of deposition with a retained record. Regulators ask for this evidence directly, so confirm what the provider captures and what you receive.
- Stability over the generations you need. Expression and product quality are assessed over a generation number that covers your intended manufacturing scale plus a margin. A stability study that stops short of what the process needs is a study you will repeat.
- Cell banking. A research or master bank is laid down with identity, sterility, mycoplasma and adventitious agent testing to a defined panel. Establish who holds the bank, where the backup is stored, and what your rights to it are if the relationship ends.
Productivity is not the only number
Titre is the headline and product quality is the decision: glycosylation, charge variants, aggregation and fragmentation determine whether the material is usable, and a high-titre clone with poor quality attributes is not a winner. Ask how quality attributes are screened and at what stage clones are eliminated on them.
Ask how many clones are carried to each stage and on what criteria they are cut. A funnel that narrows early on titre alone is cheaper to run and more likely to discard the clone you wanted.
Licences, and what travels with the line
Host lines, selection systems and some expression technologies are licensed, and the terms frequently include milestone or royalty obligations that attach to your programme rather than to the provider. Get the full licence position in writing at the contracting stage.
A line developed cheaply under restrictive terms is not cheap. This is the single most common unpleasant surprise in the category.
Common questions
- What does cell line development deliver?
- A clonally derived, documented cell line expressing your product, with clonality evidence, a stability assessment over the required generations, a cell bank with its testing package, and the process description.
- Why does clonality evidence matter?
- Regulators expect assurance that the production line descends from a single cell, and they ask for the evidence rather than the assertion. Imaging at deposition with a retained record is the usual form, and it is far easier to capture at the time than to reconstruct.
- Can I use pool material for early studies?
- Usually yes, and doing so pulls months out of a programme. Pool material gives an early read on expression and quality while cloning proceeds in parallel.
- Who owns the cell line?
- The contract decides, and the host and expression system licences sit underneath it. Confirm both before starting, because licence obligations attach to the programme and can outlast the provider relationship.
Get a shortlist for your project
Browse by service class
Sources
Cite or embed this figure
The median advertised gene synthesis price per base pair in the US research synthesis services market was $0.11 in August 2026, across 4 verified vendor service pages recorded in BioBricks Synthesis Price Index.
Cite as: "BioBricks Synthesis Price Index", updated 2026-08-24, https://biobricks.org/cell-line-development/.